Stage (next event)
Phase 3 (NDA Submission)
Catalyst Info & Data Links
TITLE: Plinabulin for All Cancer (CIN) - Phase 3
ClinicalTrial.gov (NCT03102606): Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)
ClinicalTrial.gov (NCT03294577): Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
WHAT IS THE NEXT CATALYST EVENT?
NDA Submission For Plinabulin For CIN In The U.S.
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-16-2020 BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia
06-15-2020 BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention
2020 Head-to-head comparison of the non-G-CSF small molecule single agent (SA) Plinabulin with SA pegfilgrastim for the prevention of docetaxel chemotherapy (chemo)-induced neutropenia (CIN) in the protective-1 trial.
Mechanism of Action
MECHANISM OF ACTION
Plinabulin binds to and affects the function of the protein tubulin within cells of the body, in a manner recently demonstrated to differ significantly from all other approved or advanced tubulin targeting agents. Tubulin aggregates or polymerizes inside cells to form strands called microtubules that have different functions indifferent cells. Therefore disrupting microtubules with Plinabulin has different effects in different cell types in the body.
Updated by JM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post